New Way to Target B-Cell Lymphomas 
Cancer Network
By Anna Azvolinsky, PhD | May 18, 2012 Researchers at the University of Pennsylvania have identified a protein that could be targeted to turn off B-cell lymphomas. The protein, CD19, was found to be a major regulator of B-cell neoplastic growth driven ...

 

What are Non-Hodgkin Lymphoma Survival Rate? 
Opposing Views
This article looks at the Non-Hodgkin lymphoma survival rate. Non-Hodgkin's lymphoma (NHL) is a very broad term for cancers affecting the lymphocytes in the body's immune system and varying the Non-Hodgkin lymphoma survival rate.

 

Cell Therapeutics' Lymphoma Drug Wins Conditional EU Approval 
Wall Street Journal
Cell Therapeutics Inc. (CTIC) won conditional authorization to market its treatment for non-Hodgkin B-cell lymphomas in the European Union, a key regulatory win for the drug maker. Shares were halted at $1.04 Thursday ahead of the news.
Cell Therapeutics' lymphoma drug, Pixuvri gets EU conditional marketing approval pharmabiz.com
Drug Approval! Oh, Wait, We Knew That Already. DailyFinance
Cell Therapeutics' Pixuvri receives European Union approval Pharmaceutical Business Review
24/7 Wall St. 
all 10 news articles » 

What is MALT Lymphoma? 
Opposing Views
This article looks at MALT lymphoma symptoms, MALT lymphoma being a subtype of lymphoma. 'Lymphoma' is an umbrella term that loosely refers to several dozen independent categorical types and subtypes of cancers of the lymphatic system.

 

Seattle Genetics Announces Data from Investigator Trial of ADCETRIS(TM) in ... 
MarketWatch (press release)
The study is led by principal investigator Dr. Youn H. Kim, Professor, Department of Dermatology, and Director, Multidisciplinary Cutaneous Lymphoma Program at Stanford University School of Medicine in Stanford, CA. Key findings include: -- Twelve of ...
Seattle Genetics Announces Data from Investigator Trial of ADCETRIS? in ... Genetic Engineering News (press release)
MDx/CDx Focus: AssureRx Launches ADHD PGx Test; Adcetris Phase III Study in CD ... GenomeWeb
Seattle Genetics Reports First Quarter 2012 Financial Results SunHerald.com
Boston Business Journal 
all 24 news articles » 

Identifying Appropriate Patient Groups and Drug Targets in DLBCL 
Cancer Network
Although personalized clinical medicine sparked the differential treatment of non-Hodgkin lymphomas as a larger entity over the past 20 years, through advances in morphologic and immunohistochemistry-driven classification schemes, we have made less ...

and more » 

Researchers make promising discovery in pursuit of effective lymphoma treatments 
Science Codex
"Many other lymphomas are also controlled by this pathway, so while we're optimistic that this discovery will provide a way to kill multiple myeloma cells, we're also very hopeful that this can be applied to other lymphomas and that it will have a ...

and more » 

Researchers Make Promising Discovery in Pursuit of Effective Lymphoma Treatments 
Newswise (press release)
?Many other lymphomas are also controlled by this pathway, so while we're optimistic that this discovery will provide a way to kill multiple myeloma cells, we're also very hopeful that this can be applied to other lymphomas and that it will have a ...

and more » 

Researchers make promising discovery in pursuit of effective lymphoma treatments 
Medical Xpress
"Many other lymphomas are also controlled by this pathway, so while we're optimistic that this discovery will provide a way to kill multiple myeloma cells, we're also very hopeful that this can be applied to other lymphomas and that it will have a ...

and more » 

Protein May Represent a Switch to Turn Off B cell Lymphoma 
MarketWatch (press release)
Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing ...

and more »